Ann: Appendix 4C - December 2018 Quarterly Report, page-4

Commercial sales in the Dominican Republic remain imminent (delayed a month or so by initial test kit batch production issues). Lab tests tracking to be launched in Spain and Mexico in the next 3 months.

"Proteomics International is also pursuing registration of the kit version of the test for larger scaleadoption as market demand increases. The PromarkerD kit is being used to target newcommercialisation deals in Japan, India and China, and opens the door to further commercialisationdiscussions around the world."

My read is that the kit version is the main game here and it will probably take another 12 months for global licensing, and probably 24 months for serious $$'s to start flowing in. None the less we should see PromarkerD lab test revenue starting this side of the calendar year and analytics revenue will keep growing strongly based on the following commentary;

 "Proteomics International took out the Health and Biotechnology category of theWA Industry and Export Awards on October 18. The export award reflected the company's doublingof export-derived revenue to $795,000 for the 2018 financial year, coupled with growth in long-termmarkets such as India, and expansion into new markets with the first sales to China and theNetherlands."

I would expect these two revenue streams should see the SP supported and hopefully driven up beyond its recent highs over the coming year.

And this does not factor in if anything exciting comes out of  the ongoing R&D or from the Janssen Biopharma collaboration such as the development of an effective Diabetic Kidney Disease and Heart Disease drug with the assistance of Promarker technology.

Hate the speed bumps like everyone else but I think were moving in the right direction at a good clip.. most importantly, no cash burn issue or looming threats of CR's.